Search -

Displaying 1 - 20 of 426

Sort: Relevancy | Date

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

Advertisement

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Evolocumab Wins for Primary Prevention in VESALIUS-CV

CVD Still the Leading Cause of Death and Disease Globally

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content